📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 18:52
0 analysed today
FollowTelegram
0
Today
149,939
All-time analysed
42,983
Positive
6,669
Negative
91,579
Neutral
8,640
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Rs 0.29 Cr PAT; Tejnaksh Healthcare Q1 Revenue Grows 3.7% YoY to Rs 1.93 Cr
Tejnaksh Healthcare reported a standalone total income of Rs 1.93 Cr for Q1 FY27, a marginal 3.7% increase compared to Rs 1.86 Cr in the same quarter last year. Net profit declined by 13.7% YoY to Rs 29.11 Lakhs, down from Rs 33.73 Lakhs, primarily due to an increase in other expenses. The current quarter's revenue represents only 17.5% of the TTM revenue of Rs 11 Cr, indicating a slow start to the financial year. The company remains debt-free but is operating at a very small scale with stagnant growth.
Confidence: HIGH
What changedThe company reported its first-quarter financial results for FY27, showing marginal revenue growth but a dip in net profitability.
Why it mattersAs a micro-cap healthcare provider with a Rs 28 Cr market cap, the company needs to demonstrate consistent growth to justify its valuation; current results show a slowdown relative to the previous year's average.
Total Income (Q1 FY27): Rs 1.93 CrNet Profit (Q1 FY27): Rs 0.29 CrQ1 Revenue vs TTM Revenue: 17.5%YoY Profit Growth: -13.7%Other Expenses: Rs 0.88 Cr
📅 Short termThe stock is likely to remain neutral as the results show stagnant growth and a small profit base that may not excite the market.
📈 Long termLimited structural significance unless the company initiates a major capacity expansion or hospital acquisition to move beyond its current small-scale operations.
⚠ Risk flags
- Small scale of operations
- Stagnant revenue growth
- High other expenses relative to income
Key Highlights
Total income for Q1 FY27 stood at Rs 1.93 Cr, compared to Rs 1.86 Cr in Q1 FY26.
Net profit after tax fell to Rs 29.11 Lakhs from Rs 33.73 Lakhs in the year-ago period.
Other expenses rose to Rs 87.66 Lakhs, representing approximately 45% of total income.
Earnings Per Share (EPS) for the quarter was Rs 0.14, down from Rs 0.17 in Q1 FY26.
A reversal of gratuity liability was recognized as other income following the implementation of New Labour Codes.
👀 What to Watch
Investors should monitor if the company can scale its revenue run-rate in upcoming quarters to match its TTM performance and observe the impact of 'Other Expenses' on operating margins.
Tejnaksh Healthcare Q1 FY27 Standalone Net Profit at ₹0.29 Cr, Down 42% Sequentially
Tejnaksh Healthcare reported a standalone net profit of ₹0.29 Cr for the quarter ended June 30, 2026, representing a 42.2% decline from the ₹0.50 Cr reported in the previous quarter (March 2026). Revenue from operations remained relatively flat sequentially at ₹1.93 Cr compared to ₹1.92 Cr in Q4 FY26, though it grew 3.7% year-on-year. The company's profitability was impacted by a rise in 'Other expenses', which increased to ₹87.66 lakhs from ₹76.58 lakhs in the preceding quarter. Additionally, the board approved the reappointment of Suhas Vasantrao Thorat as an Independent Director for a second term.
Confidence: HIGH
What changedThe company has reported its first-quarter financial results for FY27 and extended the tenure of a key independent board member.
Why it mattersFor a micro-cap company with a ₹28 Cr market cap, small absolute changes in expenses significantly impact net margins; the sequential drop in profit indicates recent margin pressure.
Q1 FY27 Standalone Revenue: ₹1.93 CrQ1 FY27 Standalone PAT: ₹0.29 CrQoQ Profit Growth: -42.2%Q1 Revenue vs TTM Revenue: 17.5%EPS (Q1 FY27): ₹0.14
📅 Short termThe results are unlikely to trigger significant price movement given the micro-cap nature and the sequential decline in profitability.
📈 Long termLimited structural change; the company remains a small-scale healthcare provider with stagnant revenue growth and low ROCE (6.3%).
⚠ Risk flags
- Sequential margin contraction
- High concentration in a single business segment
- Micro-cap liquidity risk
Key Highlights
Standalone revenue from operations for Q1 FY27 stood at ₹1.93 Cr, a marginal 3.7% increase over ₹1.86 Cr in Q1 FY26.
Net profit for the quarter was ₹29.11 lakhs, down from ₹50.41 lakhs in the previous quarter (March 2026).
Total expenses rose to ₹1.48 Cr in Q1 FY27, compared to ₹1.30 Cr in the previous quarter.
Earnings Per Share (EPS) for the quarter decreased to ₹0.14 from ₹0.39 in the preceding quarter.
Reappointment of Mr. Suhas Vasantrao Thorat as a Non-Executive Independent Director for a second term, subject to shareholder approval.
👀 What to Watch
Investors should monitor the company's ability to control operating expenses, particularly 'Other expenses' which consumed 45% of revenue this quarter, and watch for the consolidated results to assess the performance of subsidiaries.
